Correction to: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (European Journal of Human Genetics, (2017), 25, 4, (432-438), 10.1038/ejhg.2016.203);Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers

European Journal of Human Genetics

Volumn 25, Issue 4, 2017, Pages 432-438

  Walker, Logan C ^a   Marquart, Louise ^b   Pearson, John F ^a   Wiggins, George A R ^a   O'Mara, Tracy A ^b   Parsons, Michael T ^b,c   Barrowdale, Daniel ^d   McGuffog, Lesley ^d   Dennis, Joe ^d   Benitez, Javier ^e   Slavin, Thomas P ^f   Radice, Paolo ^g   Frost, Debra ^d   Godwin, Andrew K ^h   Meindl, Alfons ⁱ   Schmutzler, Rita Katharina ^j,k   Isaacs, Claudine ^l   Peshkin, Beth N ^l   Caldes, Trinidad ^m   Hogervorst, Frans B L ⁿ   Lazaro, Conxi ^o   Jakubowska, Anna ^p   Montagna, Marco ^q,r,s   Chen, Xiaoqing ^b   Offit, Kenneth ^t   Hulick, Peter J ^u   Andrulis, Irene L ^v   Lindblom, Annika ^w   Nussbaum, Robert L ^x   Nathanson, Katherine L ^y   Chenevix Trench, Georgia ^b   Antoniou, Antonis C ^d   Couch, Fergus J ^z   Spurdle, Amanda B ^b   more..

^a UNIVERSITY OF OTAGO   (New Zealand)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Centro Nacional de Investigaciones Oncológicas   (Spain)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^k INSTITUT CURIE   (France)

^l GEORGETOWN UNIVERSITY   (United States)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁿ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^o BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^p POMERANIAN MEDICAL UNIVERSITY   (Poland)

^q VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^r PETER MACCALLUM CANCER CENTRE   (Australia)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^u NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^v MOUNT SINAI HOSPITAL   (Canada)

^w KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^x UNIVERSITY OF CALIFORNIA   (United States)

^y UNIVERSITY OF PENNSYLVANIA   (United States)

^z MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; CYP2A7 PROTEIN, HUMAN; CYTOCHROME P450 FAMILY 2; DNA BINDING PROTEIN; GLUTAMATE CARBOXYPEPTIDASE II; NAALADL2 PROTEIN, HUMAN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PSG5 PROTEIN, HUMAN; TRANSCRIPTION FACTOR II; UNSPECIFIC MONOOXYGENASE; ZNF385A PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER RISK; COHORT ANALYSIS; COPY NUMBER VARIATION; FEMALE; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENETIC ALGORITHM; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MODIFIER GENE; OVARY CANCER; OVARY TISSUE; OVERLAPPING GENE; PRIORITY JOURNAL; RISK FACTOR; BREAST TUMOR; GENETICS; OVARY TUMOR;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BRCA1 PROTEIN; BREAST NEOPLASMS; CYTOCHROME P450 FAMILY 2; DNA COPY NUMBER VARIATIONS; DNA-BINDING PROTEINS; FEMALE; GENES, MODIFIER; GLUTAMATE CARBOXYPEPTIDASE II; HETEROZYGOTE; HUMANS; OVARIAN NEOPLASMS; PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEINS; TRANSCRIPTION FACTORS, TFII;

EID: 85011277736     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/s41431-018-0216-1     Document Type: Erratum

References (34)

1. Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822.
2. Milne RL, Antoniou AC: Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011; 22: i11-i17.
3. Couch FJ, Wang X, McGuffog L et al: Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013; 9: e1003212.
4. Gaudet MM, Kuchenbaecker KB, Vijai J et al: Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet 2013; 9: e1003173.
5. Bojesen SE, Pooley KA, Johnatty SE et al: Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45: 371-384, 384e1-2.
6. Kuchenbaecker KB, Neuhausen SL, Robson M et al: Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014; 16: 3416.
7. Zarrei M, MacDonald JR, Merico D, Scherer SW: A copy number variation map of the human genome. Nat Rev Genet 2015; 16: 172-183.
8. Stranger BE, Forrest MS, Dunning M et al: Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315: 848-853.
9. Fanciulli M, Petretto E, Aitman TJ: Gene copy number variation and common human disease. Clin Genet 2010; 77: 201-213.
10. Krepischi AC, Pearson PL, Rosenberg C: Germline copy number variations and cancer predisposition. Future Oncol 2012; 8: 441-450.
11. Qi G, Xiong H, Zhou C: APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women. Tumour Biol 2014; 35: 5723-5726.
12. Long J, Delahanty RJ, Li G et al: A common deletion in the APOBEC3 genes and breast cancer risk. J Natl Cancer Inst 2013; 105: 573-579.
13. Xuan D, Li G, Cai Q et al: APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 2013; 34: 2240-2243.
14. Antoniou AC, Wang X, Fredericksen ZS et al: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42: 885-892.
15. Wang K, Li M, Hadley D et al: PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res 2007; 17: 1665-1674.
16. Colella S, Yau C, Taylor JM et al: QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res 2007; 35: 2013-2025.
17. Frank B, Bermejo JL, Hemminki K et al: Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis 2007; 28: 1442-1445.
18. Walsh T, Casadei S, Coats KH et al: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379-1388.
19. Diehn M, Sherlock G, Binkley G et al: SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 2003; 31: 219-223.
20. Giardine B, Riemer C, Hardison RC et al: Galaxy: a platform for interactive large-scale genome analysis. Genome Res 2005; 15: 1451-1455.
21. Blankenberg D, Von Kuster G, Coraor N et al: Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19: Unit 19 10 11-Unit 19 10 21.
22. Goecks J, Nekrutenko A, Taylor J: Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010; 11: R86.
23. Barnes DR, Lee A, Easton DF, Antoniou AC: Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol 2012; 36: 274-291.
24. Dialsingh I, Austin SR, Altman NS: Estimating the proportion of true null hypotheses when the statistics are discrete. Bioinformatics 2015; 31: 2303-2309.
25. Walker LC, Wiggins GAR, Pearson JF: The role of constitutional copy number variants in breast cancer. Microarrays 2015; 4: 17.
26. ENCODE Project Consortium: An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57-74.
27. Roadmap Epigenomics C, Kundaje A, Meuleman W et al: Integrative analysis of 111 reference human epigenomes. Nature 2015; 518: 317-330.
28. Hnisz D, Abraham BJ, Lee TI et al: Super-enhancers in the control of cell identity and disease. Cell 2013; 155: 934-947.
29. Nakano M, Fukushima Y, Yokota S et al: CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. Drug Metabo Dispos 2015; 43: 703-712.
30. Xu C, Goodz S, Sellers EM, Tyndale RF: CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 2002; 54: 1245-1256.
31. Liu YL, Xu Y, Li F, Chen H, Guo SL: CYP2A6 deletion polymorphism is associated with decreased susceptibility of lung cancer in Asian smokers: a meta-analysis. Tumour Biol 2013; 34: 2651-2657.
32. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
33. Mjelle R, Hegre SA, Aas PA et al: Cell cycle regulation of human DNA repair and chromatin remodeling genes. DNA Repair 2015; 30: 53-67.
34. Benjamini Y, Yekutieli D: The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001; 29: 1165-1188.